RxDoctor Payments Data

Vincent Cubelli, MD

Urology · Denville, NJNPI 1053353474

Payments from drug & device makers

$3,774in general payments, 2019–2025

Across 186 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$334
  • Procept Biorobotics Corporation$315
  • AbbVie$309
  • Johnson & Johnson$292
  • Myriad Genetic Laboratories, Inc.$236
  • Astellas Pharma US Inc$232
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$3,66697%
  • Education$1083%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,774 in reported general payments places this provider in the 60th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$329,351
Medicare patients
737
Services billed
15,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron163$134,218
GemtesaVibegron108$118,266
Tamsulosin Hcl1,046$22,736
Tolterodine Tartrate ErTolterodine Tartrate71$5,446
PremarinEstrogens, Conjugated12$5,339
Potassium Citrate ErPotassium Citrate68$5,008
Alfuzosin Hcl ErAlfuzosin Hcl164$4,395
Finasteride270$4,104
Oxybutynin Chloride ErOxybutynin Chloride106$3,169
Trospium Chloride43$3,136
Silodosin46$3,007
Testosterone29$2,589
Solifenacin Succinate34$1,841
Estradiol33$1,531
Methenamine Hippurate16$1,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$232$134,218163 claims
Sumitomo Pharma America, Inc.Gemtesa$334$118,266108 claims
PfizerPremarin$113$5,33912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 401 urology providers in New Jersey.

Other urology in Denville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →